Organogenesis Holdings Overview
- Founded
-
1985
- Status
-
Public
- Employees
-
950
- Stock Symbol
-
ORGO
- Investments
-
5
- Share Price
-
$6.19
- (As of Friday Closing)
Organogenesis Holdings General Information
Description
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 85 Dan Road
- Canton, MA 02021
- United States
+1 (781) 000-0000
Organogenesis Holdings Timeline
Organogenesis Holdings Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.19 | $5.92 | $4.62 - $17.50 | $799M | 129M | 1.09M | $0.66 |
Organogenesis Holdings Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 999,565 | 1,198,520 | 1,039,817 | 576,879 |
| Revenue | 463,624 | 468,059 | 338,298 | 260,981 |
| EBITDA | 76,987 | 87,698 | 37,226 | (19,737) |
| Net Income | 85,046 | 94,902 | 17,234 | (38,709) |
| Total Assets | 436,272 | 443,259 | 290,218 | 220,687 |
| Total Debt | 130,194 | 132,303 | 84,771 | 100,606 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Organogenesis Holdings Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Organogenesis Holdings Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercializa
Biotechnology
Canton, MA
950
As of 2021
00000
00000000
00000
000000
luptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non pro
0000000000000
Marietta, GA
000
As of 0000
00000
000000000
00000
000000
ectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim
0000 000000000
San Diego, CA
00
As of 0000
000.00
000000000
000.00
Add Comparison
Organogenesis Holdings Competitors (22)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mimedx | Corporation | Marietta, GA | 000 | 00000 | 000000000 | 00000 |
| 00000000 | Formerly VC-backed | San Diego, CA | 00 | 000.00 | 000000000 | 000.00 |
| 000000000 | Corporation | Melbourne, Australia | 00 | 00000 | 000000000 | 00000 |
| 00000000 | Formerly VC-backed | South San Francisco, CA | 00 | 00000 | 000000000 | 00000 |
| 00000000 | Formerly VC-backed | Durham, NC | 000 | 00000 | 000000000 | 00000 |
Organogenesis Holdings Patents
Organogenesis Holdings Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210311022-A1 | Methods, kits and compositions for characterizing an anti-inflammatory response of a product | Pending | 27-Mar-2020 | 00000000000 | |
| US-20200147144-A1 | Methods of treating joint disease, disorders and conditions with tissue inhibitors of matrix metalloproteinases | Pending | 31-Mar-2015 | 000000000 | |
| US-20160287641-A1 | Methods of treating joint diseases, disorders, and conditions with tissue inhibitors of matrix metalloproteinases | Granted | 31-Mar-2015 | 000000000 | |
| US-10576107-B2 | Methods of treating joint diseases, disorders, and conditions with tissue inhibitors of matrix metalloproteinases | Active | 31-Mar-2015 | 000000000 | 0 |
| US-20210393702-A1 | Methods of treating chronic wounds with amniotic fluid having elevated levels of tissue inhibitors of matrix metalloproteinases | Pending | 03-Mar-2015 | A61K35/50 |
Organogenesis Holdings Executive Team (10)
Organogenesis Holdings Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000 0000 | Organogenesis Holdings | Chairman & Board Member | 000 0000 |
| 000000 000000000 | Organogenesis Holdings | Board Member | 000 0000 |
| 00000 00000 | Organogenesis Holdings | Board Member | 000 0000 |
| 0000 0000000000 00. | Organogenesis Holdings | Director, President and Chief Executive Officer | 000 0000 |
| 00000 00000000 | Self | Board Member | 000 0000 |
Organogenesis Holdings Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Organogenesis Holdings Acquisitions (5)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000 000000000 | 17-Sep-2020 | 0000000000 | 0000 | Medical Supplies | 0000 0000 |
| 000000 000000 | 10-Dec-2018 | 0000000000 | Special Purpose Acquisition Company (SPAC) | 0000 0000 | |
| 000000 000000 | 24-Mar-2017 | 0000000000 | 000.00 | Surgical Devices | 0000 0000 |
| 00000 (000000 | 17-Jan-2014 | 0000000000 | 00000 | Pharmaceuticals | |
| NanoMatrix | 25-Feb-2008 | Merger/Acquisition | Biotechnology | 00000 000 |
Organogenesis Holdings Subsidiaries (2)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| NuTech Medical | Surgical Devices | Birmingham, AL | 1994 |
| 000 00000000000 | Medical Supplies | Largo, FL |